When transferring tissue regenerative strategies involving skeletal stem cells to human application, consideration needs to be given to factors that may affect the function of the cells that are transferred. Local anaesthetics are frequently used during surgical procedures, either administered directly into the operative site or infiltrated subcutaneously around the wound. The aim of this study was to investigate the effects of commonly used local anaesthetics on the morphology, function and survival of human adult skeletal stem cells.
When transferring tissue regenerative strategies involving skeletal stem cells to human application, consideration needs to be given to factors that may affect the function of the cells that are transferred. Local anaesthetics are frequently used during surgical procedures, either administered directly into the operative site or infiltrated subcutaneously around the wound. The aim of this study was to investigate the effects of commonly used local anaesthetics on the morphology, function and survival of human adult skeletal stem cells.
Cells from three patients who were undergoing elective hip replacement were harvested and incubated for two hours with 1% lidocaine, 0.5% levobupivacaine or 0.5% bupivacaine hydrochloride solutions. Viability was quantified using WST-1 and DNA assays. Viability and morphology were further characterised using CellTracker Green/Ethidium Homodimer-1 immunocytochemistry and function was assessed by an alkaline phosphatase assay. An additional group was cultured for a further seven days to allow potential recovery of the cells after removal of the local anaesthetic.
A statistically significant and dose dependent reduction in cell viability and number was observed in the cell cultures exposed to all three local anaesthetics at concentrations of 25% and 50%, and this was maintained even following culture for a further seven days.
This study indicates that certain local anaesthetic agents in widespread clinical use are deleterious to skeletal progenitor cells when studied in vitro; this might have relevance in clinical applications.
Although the therapeutic principles of bone grafting have been employed for well over 100 years, 1, 2 the use of skeletal cell progenitor populations together with tissue engineered products has only recently extended to orthopaedic applications. In addition to providing an osteoconductive and osteo-inductive structure to aid bone healing, such composites critically contain undifferentiated skeletal stem cells (SSCs), often referred to as mesenchymal stem cells, which augment de novo bone production in the areas with limited or poor bone stock. 3 SSCs in isolation have also been shown to provide theoretical beneficial effects in an increasing number of disorders. 4, 5 Hernigou et al 6 showed an increased rate of healing in tibial nonunions when injected with ex vivo expanded SSCs. In addition, SSCs have been used for the treatment of cartilage defects, bone regeneration, and soft-tissue pathologies such as tendinopathies or ligament injuries. [6] [7] [8] Typically, the inclusion of stem cells into a therapeutic procedure requires only a modest change in the established procedure in order to accommodate the novel construct. 9 However, the efficacy of the new technique may be compromised by aspects of the established procedure, such as temperature changes, infection, wound cleansing using pulsatile lavage, as well as the use of ancillary products such as antibiotics or local anaesthetics (LAs).
The toxic effects of common LAs on a number of differentiated cell types, such as chondrocytes, have previously been documented, [10] [11] [12] [13] [14] but we are not aware of any published research on LA toxicity on skeletal progenitor cells. In addition, LAs may also affect established procedures, such as microfracture, which rely on autologous SSC populations for their success.
The aim of this in vitro study was to investigate the effects of three LAs in routine use in orthopaedic practice on SSC function and survival, in order to establish their individual toxicities over a range of physiological concentrations.
Materials and Methods
The experimental protocol is demonstrated in Figure 1 .
Skeletal cell populations (primary passage) were obtained from the bone marrow of three patients (two male patients aged 66 years and 39 years (M66 and M39) and one female aged 72 years (F72)) undergoing primary total hip replacement with the approval of the Local Ethics Committee as described previously. 15 After expansion, cell populations were diluted with basal medium to a concentration of 5×10 4 cells/ml, and 1 ml of this solution was added to each well of a standard 12 well plate. In total ten plates were seeded for patients M66 and F72, and 20 for M39, giving a total of 120 wells per patient (240 wells for M39) for experimentation. The cells were then grown to confluence over a period of seven days. The experimental group was doubled for one patient (M39), in order that a delayed analysis could also be performed one week following LA exposure, so that any delayed deleterious effects on the surviving cell population could be assessed.
Three local anaesthetic solutions i) 1% lidocaine hydrochloride (Hameln Pharmaceuticals Ltd, Gloucester, United Kingdom), ii) 0.5% bupivacaine hydrochloride (AstraZenica UK Ltd, Luton, United Kingdom), and iii) 0.5% levobupivacaine hydrochloride (Abbott Laboratories Ltd, Queensborough, United Kingdom) were obtained from commercial sources in their 'ready to use preparation', and diluted in basal medium to produce 50:50, 25:75, and 10:90 LA-to-basal medium solutions by volume. In order to prevent cellular insult through lack of nutrients alone, and to ensure that there was always enough medium for cellular metabolism and diffusion, the maximum concentration of LA used was a 50:50 (v/v) dilution. Had a 100% solution been used it would have been impossible to tell if any toxicity was due to the LA, or simply the absence of normal factors required for cell survival over the incubation period. Dilutions were based on the ready to use preparations rather than the specific percentage LA solution concentrations, as in the clinical situation this was the recommended concentration at which the specific LA has proven efficacy, and thus the LAs were comparable to each other in terms of SSC toxicity. Thus experimental concentrations of lidocaine were twice that of bupivacaine and levobupivacaine (Table I) enabling direct comparison between LAs as used in a surgical setting, and has been standard practice in related published reports. 10, 16, 17 Upon cell confluence, 1 ml of each of the three LA solutions at each of the three concentrations (nine groups per patient) was added to 12 wells (108 wells in total), with 1 ml basal medium alone added to the remaining 12 wells to act as controls. The procedure was repeated for the second set of M39 cells. Following incubation for two hours, the LA solutions were removed, the cells washed in phosphate buffered saline (PBS), and incubated overnight in basal medium before analysis. The second set of M39 cells underwent further incubation in basal medium of seven days, with PBS washes every three days prior to analysis. The experimental set-up was broadly comparable to an in vivo scenario such as arthroscopy of the knee, where intraarticular injection of LA is used following the use of SSC containing constructs for regeneration of cartilage. Any scaffolds and cells could potentially be directly bathed in the undiluted LA for a considerable time. 7 An incubation of two hours was chosen in accordance with other studies, because of the similar half-lives of the LAs, and the likely time that any tissue-engineered construct would be in direct contact with LA prior to absorption either by local vessels or via the synovial vessels if given intra-articularly. 18, 19 Furthermore, the lower concentrations of LAs used in vitro could be comparable to the in vivo concentrations reached in bone containing tissue-engineered constructs if the LA was injected into the soft-tissues surrounding the region for pain relief. Water-soluble Tetrazolium salts (WST-1) assay. The number and viability of cells following LA exposure at the three concentrations were quantified using the WST-1 assay (nine groups per patient cell population + controls). After removal of the basal medium and washing in PBS, 1 ml of 1:10 dilution WST-1 substrate (Roche Ltd, Welwyn Garden City, United Kingdom) was added to four of the 12 wells of each group. At two hours, three 100 μl aliquots of substrate were removed from each well and read using a BioTek ELx-800 universal microplate spectrophotometer (BioTek, Potton, United Kingdom) at a wavelength of 410 nm. An increase in absorbance value, representing an increase in optical density of the substrate, indicated increased cell number and viability. Means and standard deviations (SD) were calculated for the optical densities of each group and proportional reduction (%) compared with controls. DNA assay. Cell number (but not viability) was also determined using a standard DNA PicoGreen assay. 20 In brief, cells were washed in PBS and fixed in 90% ethanol prior to drying in air. The cells were then rewashed in PBS and lysed in 1 ml of 0.5% Triton X-100 (Sigma-Aldrich, Gillingham, United Kingdom) before undergoing three freeze-thaw cycles and mechanical lysis. Cell lysate was measured for DNA content using PicoGreen (Molecular Probes, Paisley, United Kingdom) according to the manufacturer's protocol. A total of 10 μl of lysate was run in triplicate for each well on a plate against standards, analysed using a BioTek FLx-800 microplate fluorescent reader (BioTek).
CellTracker Green (CTG) was used to label viable cells and Ethidium Homodimer-1 (EH-1) for necrotic cell nuclei (live/dead stain). The samples were washed in PBS and incubated for 90 minutes in 1 ml of standard CTG/ EH-1 solution (10 μg/ml CTG, 5 μg/ml EH-1). Samples were fixed in ethanol and stored in PBS prior to fluorescent microscopy.
However, experimental observation showed that due to PBS washes after the LA exposure and after the incubation periods, the DNA from dead cells would have largely degraded or been washed away, making this assay an effective secondary measure of the number of viable cells. Alkaline phosphatase assay. Under normal circumstances a proportion of SSCs will undergo osteoblastic differentiation if incubated in standard basal media, 21 which would be desirable in osteoregenerative medicine. In order to compare whether the proportionate differentiation potential of the cell populations exposed to the LAs was affected, an alkaline phosphatase (ALP) assay was used seven days following LA exposure (in the M39 cell population). ALP in the cell lysate (as obtained for the DNA assay) was measured using p-nitrophenyl phosphate (pNPP) as the substrate in 2-amino-2-methyl-1-propanol alkaline buffer solution (Sigma, Poole, United Kingdom) according to the manufacturer's protocol. A total of 10 μl of lysate was run in triplicate for each well on a plate against standards and analysed using a BioTek ELx-800 microplate reader. Alkaline phosphatase stain. Cell morphology and expression of ALP was examined in the final two of 12 wells for each LA group in the M39 cell population after seven days further incubation in basal media. In brief, cells were fixed in 95% ethanol followed by incubation for 45 minutes in 1 ml of 40 μl/ml naphthol AS-MX phosphate solution (SigmaAldrich) with 0.24 μg/ml fast violet salt (Sigma-Aldrich) followed by rinsing prior to microscopy. Statistical analysis. All experimental groups (three patients) were replicated four times (12 samples in total). Statistical analysis was performed using GraphPad Prism software version 3.02 (GraphPad Software Inc., La Jolla, California). Statistical comparison was made using a Mann-Whitney U test with a p-value < 0.05 taken to be significant.
Results
Lidocaine. Analysis of cell viability and proliferation using the WST-1 assay demonstrated a toxic effect of lidocaine on skeletal cell populations that was concentration-dependent. As shown in Figure 2 , negligible toxicity was observed in each of the three primary skeletal cell populations following culture in 10% lidocaine. In contrast, incubation in both 25% and 50% solutions resulted in a significant fall in cell viability with reductions in the mean optical density from 0.83 (SD 0.22) to 0.57 (SD 0.12) (33%, p = 0.02) and to 0.24 (SD 0.08) (70%, p < 0.001), respectively. Similar observations were recorded for DNA analysis with a reduction in mean DNA concentration for 25% and 50%
solutions from 442.34 ng/ml (SD 31.39) to 285.74 ng/ml (SD 11.51) (35%, p = 0.03) and to 89.14 ng/ml (SD 9.74) (80%, p < 0.001), respectively (Fig. 3) . Furthermore, the inhibition of cell proliferation was maintained seven days after LA exposure with a significant reduction of mean optical densities from 0.72 (SD 0.03) to 0.59 (SD 0.09) (18%, p = 0.01) and 0.72 (SD 0.03) to 0.4 (SD 0.10) (45%, p = 0.01) in the 25% and 50% solutions, respectively, as measured by WST-1 assay (Fig. 4) , with a corresponding persistent drop in mean DNA concentration from 187.08 ng/ml (SD 52.56) to 56.32 ng/ml (SD 9.47) (70%, p = 0.03) and 187.08 ng/ml (SD 52.56) to 46.96 ng/ml (SD 10.79) (75%, p = 0.03) respectively (Fig. 5) . Bupivacaine. A similar concentration-dependant toxicity was observed in cells exposed to bupivacaine. As illustrated in Figure 2 , WST-1 assay demonstrated no significant difference in the cells exposed to the 10% solution compared with the controls (p = 0.21). However, the drop in optical density was significant for both the 25% and 50% solutions where the mean drop was 0.83 (SD 0.32) to 0.25 (SD 0.03) (68%, p < 0.001) and to 0.23 (SD 0.06) (72%, p < 0.001), respectively. These results were supported by DNA analysis (Fig. 3) , where a significant reduction in the mean DNA concentration from the cell lysate was observed in the 25% and 50% solutions respectively (both p < 0.001). This appeared to be a long lasting effect in those cells exposed to the 50% bupivacaine solutions where a reduction from 0.72 (SD 0.03) to 0.29 (SD 0.07) (59%) was measured on the WST-1 assay (p = 0.03) (Fig. 4) , and a decrease in the mean DNA concentration for the 50% bupivacaine solution was from 187.08 ng/ml (SD 52.56) to 50.49 ng/ml (SD 16.80) (73%, p = 0.01) (Fig. 5) . Barchart showing the mean cell proliferation on WST-1 assay, 24 hours after exposure of two hours to different concentrations of local anaesthetic (0%, 10%, 25% and 50%). Cell viability was reduced with increasing concentration of local anaesthetic, although the effect is less marked for cells exposed to levobupivacaine. Error bars show the standard deviation (ns, not significant; * p < 0.05, ** p < 0.001, absolute p-values given in Results). Barchart showing the combined mean DNA assay of cells, 24 hours after exposure of two hours to increasing concentrations of local anaesthetics (0%, 10%, 25% and 50%). A reduction in cell numbers can be seen with increasing concentrations of lidocaine and bupivacaine, There was no significant change in DNA for cells exposed to levobupivacaine at all concentrations examined. Error bars represent standard deviations (ns, not significant; * p < 0.05, ** p < 0.001, absolute p-values given in Results). Barchart showing the mean cell proliferation on WST-1 assay, seven days after exposure of two hours to different concentrations of local anaesthetic (0%, 10%, 25% and 50%). A persistent reduction in cell viability was observed with increasing concentrations of lidocaine and bupivacaine. Note restoration of cell viability in cells exposed to levobupivacaine following seven days recovery. Error bars represent standard deviations (ns, not significant; * p < 0.01, absolute p-values given in Results).
Levobupivacaine. The toxic effects of levobupivacaine were not as significant as for lidocaine or bupivacaine. The WST-1 assay showed no significant mean loss of cell viability in the 10% solution (p = 0.07), and in both the 25% and 50% solutions the mean reduction in optical density was only from 0.83 (SD 0.32) to 0.65 (SD 0.34) (25%, p = 0.02) and to 0.64 (SD 0.31) (24%, p = 0.02) respectively (Fig. 2) . This was supported by the DNA analysis (Fig. 3) . Furthermore, the toxic effect of levobupivacaine appeared to be transient, as following the seven day recovery period the surviving cell population had proliferated such that the total viability was not significantly different from that in the control group at all LA incubation concentrations. The cell population recovery observed by the WST-1 analysis was also seen following DNA analysis (Figs 4 and 5) . Cell viability and necrosis were examined using CTG/EH-1 immunocytochemistry. In the cell populations of all three patients, necrosis increased in proportion with LA concentration, as shown by the number of cell nuclei staining red with EH-1 (Fig. 6) . Necrosis was exacerbated further in those cells exposed to lidocaine or bupivacaine whereas cells exposed to levobupivacaine had markedly reduced evidence of cell death, although at higher power cytoplasmic perforations were evident, suggesting early toxicity.
There was a reduction in mean ALP activity in cells exposed to all LAs (Fig. 7) , although this was only significant in the 25% and 50% lidocaine solutions where there was a mean reduction from 38.61 nmol pNNP/ml/hr (SD 19.46) to 6.51 nmol pNNP/ml/hr (SD 1.01) and 6.51 nmol pNNP/ml/hr (SD 1.78) (both p = 0.03), and in the 25% and 50% bupivacaine solutions where the mean reduction recorded was from 38.61 nmol pNNP/ml/hr (SD 19.46) to 5.04 nmol pNNP/ml/hr (SD 1.51) (86% p = 0.03) and 100% from 38.61 nmol pNNP/ml/hr (SD 19.46) to 0.00 nmol pNNP/ml/hr (SD 3.55) (100%, p = 0.03) respectively. Barchart showing the combined mean DNA assay of cells, seven days after exposure of two hours to increasing concentrations of local anaesthetics (0%, 10%, 25% and 50%). A persistent reduction in cell numbers exposed to high concentrations of lidocaine and bupivacaine can be seen, but similar numbers in samples exposed to levobupivacaine compared with controls. Error bars represent the standard deviations (* p < 0.05, absolute p-values given in Results). A concentration dependant decrease in ALP staining was also observed one week following LA exposure (Fig. 8) and there was also a substantial reduction in cell density corresponding to increasing concentrations of LA, although this effect was less dramatic with levobupivacaine.
Controls

Discussion
These studies indicate that certain LAs used at clinically relevant concentrations are deleterious to skeletal stem cells. Specifically, bupivacaine, the most widely used anaesthetic for post-operative intra-articular use, 22 showed significant toxicity to cells following exposure for just two hours, even at 25% concentration. Similarly, lidocaine induced toxic effects at only 25% normal clinically-used concentrations. Only levobupivacaine (the S-enantiomer of bupivacaine), had reduced cell toxicity compared with the other LAs, an effect maintained at culture of seven days following removal of the LA, when there was a negligible persistent reduction in total cell activity in the levobupivacaine group, indicating that the cell population was able to recover.
From a tissue-engineering perspective, as the use of intraarticular constructs incorporating SSCs becomes more commonplace, for example during cartilage regeneration procedures, 7 the choice of LA would appear important. The present in vitro study suggests that intra-articular use of bupivacaine in such applications should be avoided. In addition, lidocaine is often used subcutaneously during minor procedures such as digital ring blocks. 23 Despite administration of this LA several centimetres from any reparative constructs in a tissue-engineering strategy, given the concentration required to produce toxicity is so low, this might be harmful to the cells. Levobupivacaine is less commonly used in clinical practice, but is still indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults and infiltration analgesia in children. 24 The comparatively reduced toxicity of levobupivacaine on SSCs found in this study is consistent with the recorded reduction in cardiovascular and central nervous system toxicity in animal and human studies, and it is probable that the stereoisomeric differences account for this. 25 Protein binding of levobupivacaine is more than 97%, compared with 95% bupivacaine, and it is the free fraction of the total concentration that can have an action on other tissues, 26 causing the unwanted side-effects, and producing the toxic manifestations.
The toxic effects of LAs on a number of cell types have been extensively investigated both in vitro and in vivo. Nole, Munson and Fulkerson 27 found reduced proteoglycan synthesis in both explanted porcine and canine cartilage when exposed to bupivacaine. Furthermore, Gomoll et al 28 showed that continuous infusion of bupivacaine into the rabbit shoulder resulted in significant histopathological and metabolic changes in the articular cartilage, and they recommended a cautious approach for the use of continuous post-operative analgesic infusions. From an orthopaedic perspective, reductions in specific cellular activities as a consequence of cell necrosis have also been attributed to bupivacaine exposure in myocytes and intervertebral disc cells. 11, 29 A similar study to the present investigation was carried out by Piper and Kim, 10 who compared the toxic effects of bupivacaine and ropivacaine on human articular chondrocytes. They found that a small change to the molecular structure resulted in significantly reduced toxicity of ropivacaine to chondrocytes. However these effects were only analysed up to 24 hours following exposure, and a subsequent study observed toxic effects of ropivacaine when measured after 120 hours. 16 Lidocaine has similar harmful effects to other certain differentiated cell types. Grishko et al 16 showed that exposure to lidocaine (as well as bupivacaine and ropivacaine) resulted in mitochondrial dysfunction and apoptosis in cultured human chondrocytes, whereas Karpie and Chu 30 also reported chondrotoxic effects of 1% and 2% lidocaine on bovine chondrocytes. The toxicity of lidocaine on mature human articular chondrocytes appears to be both dose-and time-related in vitro. 12 Lidocaine also appears to have toxic effects on other cell types, including urothelial cells 31 and retinal ganglion cells, 32 although surprisingly Rabinovitch and De Stefano 33 have described a technique of re-plating cell suspensions after tissue culture to avoid the use of proteolytic enzymes, by replacing trypsin with lidocaine, with no apparent detrimental effects. The latter study may provide a clue as to the potential mechanism for toxicity, as the lidocaine clearly disrupts intercellular adherence after only brief exposure, to enable cell re-plating. Such effects could interfere with the normal function of these cells, particularly if adherence and replication on a construct is required.
To date, the mechanisms of LA-induced cell toxicity remain unclear, although the induction of apoptosis via mitochondrial damage, caspase activation, inhibition of tyrosine kinase, and blockage of sodium channels, as well as direct necrotic effects, including altered calcium metabolism, free radical damage and changes in membrane fluidity have all been implicated. [34] [35] [36] To our knowledge this is the first study to report the toxic effects of LAs on skeletal progenitor cells. Kim et al 18 have examined the effects of lidocaine on rat musclederived progenitor cells in a urinary incontinence model. They found minimal cytotoxicity of lidocaine at a physiological concentration, concluding that this LA could be safely used for analgesia in a periurethral muscle-derived progenitor cell injection without decreasing the efficacy of the therapy. This model was, however, wholly different to the current study as only lidocaine was tested and the cells under test were specifically cultured such that they were highly enriched for differentiated myogenic cells. Our study is an in vitro model, and caution must be applied when extrapolating our observations to the clinical situation. However, given the short half life of LA, the fact that significant toxicity occurs with a two-hour exposure, and in given situations such as cartilage regenerative procedures, tissue-engineered products can be in direct contact with LA, this in vitro study is appropriate to model the direct toxic effects of LA on SSC seeded constructs at the time of implantation.
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